<DOC>
	<DOCNO>NCT02264418</DOCNO>
	<brief_summary>The purpose first-in-human study evaluate safety tolerability escalate dos ODM-203 subject advance solid tumour determine maximum tolerate dose dose limit toxicity .</brief_summary>
	<brief_title>Safety Tolerability ODM-203 Subjects With Advanced Solid Tumours</brief_title>
	<detailed_description>The safety profile ODM-203 explore together pharmacokinetics , pharmacodynamics tumour response treatment ODM-203 recommend dose regimen clinical study . The pharmacokinetic property ODM 203 evaluate single multiple dose administration different dose level</detailed_description>
	<criteria>Written inform consent Male female subject 18 year age Subjects histologically cytologically confirm locally advanced metastatic tumour . Subjects Part 2 tumour/genetic aberration . Availability tumour sample genetic analysis Adequate haemopoietic , hepatic renal function Eastern Cooperative Oncology Group performance status 0 1 Serum mineral level phosphate : 2.5 mg/dl ; calcium : 8.8 mg/dl ; magnesium : 1.2 mg/dl ; potassium : 11.7 mg/dl ; sodium : 299mg/dl . Recovery reversible adverse event previous systemic anticancer therapy baseline grade 1 exception alopecia ; stable neuropathy grade 2 induced previous cancer treatment Life expectancy 12 week Any prior anti VEGFR/FGFR treatment related AE judgement investigator consider severe/life threatening Subjects receive warfarin Active central nervous system metastasis control prior surgery/radiotherapy and/or low dose steroid 4 week Subjects current evidence endocrine alteration calciumphosphate homeostasis Concomitant therapy know increase serum phosphorus and/or calcium level discontinue switched different therapy permit within 14 day first dose ODM203 . Significant cardiovascular conditions/circumstances follow : active unstable cardio/cerebrovascular disease b Uncontrolled hypertension ( systolic blood pressure ≥ 150mmHg and/or diastolic blood pressure ≥ 90mg Hg optimise antihypertensive therapy . c history severe arrhythmia , familial arrhythmia , conduction abnormality congenital long QT syndrome dConcomitant therapy know prolong QT interval associate risk Torsades de Pointes permit within 7 day first dose ODM 203 e Repeatable prolongation QTcF interval ≥ 450 msec clinically significant abnormality ECG screen 2 3 recording f Left ventricular ejection fraction &lt; 50 % screening Subjects receive systemic anticancer treatment prior first dose ODM203 within follow timeframes : le 28 day since last dose antineoplastic therapy and/or 28 day wide field radiotherapy 14 day limit field radiation palliation Major surgery serious infection within 21 day first dose ODM203 Known gastrointestinal disease procedure may affect absorption ODM 203 Serious concurrent medical condition psychiatric illness History and/or current evidence ectopic mineralisation/calcification Known active past history primary malignancy Female child bear potential Female child bear potential male subject female partner child bear potential agree use effective contraception study 3 month last dose ODM 203 Known hypersensitivity study treatment excipients Any condition opinion investigator would impair subject 's ability comply study procedure Participation another interventional clinical trial/ concurrent treatment investigational drug within 4 week prior start treatment ODM 203</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Solid tumour</keyword>
</DOC>